CRSP CRISPR Therapeutics AG
Healthcare$51.59+2.44%ClosedMarket Cap: $4.98B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.67
P/S
1183.81
EV/EBITDA
-10.34
DCF Value
$-0.57
FCF Yield
-8.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-5360.9%
Operating Margin
-13408.3%
Net Margin
-13856.5%
ROE
-30.9%
ROA
-20.9%
ROIC
-21.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.5M | -3346.4% | $-130.2M | $-122.9M | $— | — |
| Q4 null | $864.0K | -6770.8% | $-154.8M | $-130.6M | $— | — |
| FY null | $3.5M | -6537.0% | $-568.3M | $-581.6M | $— | — |
| Q3 null | $889.0K | -7177.1% | $-132.1M | $-106.4M | $— | — |
| Q2 null | $892.0K | -5477.7% | $-133.1M | $-208.5M | $— | — |
| Q1 null | $865.0K | -6548.4% | $-148.4M | $-136.0M | $— | — |
| Q4 null | $35.0M | 100.0% | $-64.6M | $-37.3M | $— | — |
| FY null | $35.0M | -215.0% | $-466.6M | $-366.3M | $— | — |
| Q3 null | $602.0K | -2550.0% | $-110.1M | $-85.9M | $— | — |
| Q2 null | $517.0K | -10920.5% | $-151.3M | $-126.4M | $— | — |
| Q1 null | $504.0K | -10177.6% | $-140.6M | $-116.6M | $— | — |
| Q4 2023 | $200.0M | 90.0% | $69.6M | $89.3M | $1.10 | — |